Skip to Main content Skip to Navigation
Journal articles

Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity.

Abstract : Adrenocortical carcinoma (ACC) presents a high risk of relapse and metastases with outcomes not improving despite extensive research and new targeted therapies. We recently showed that the Hedgehog receptor Patched is expressed in ACC, where it strongly contributes to doxorubicin efflux and treatment resistance. Here, we report the identification of a new inhibitor of Patched drug efflux, the anti-histaminergic drug astemizole. We show that astemizole enhances the cytotoxic, proapoptotic, antiproliferative and anticlonogenic effects of doxorubicin on ACC cells at concentrations of astemizole or doxorubicin that are not effective by themselves. Our results suggest that a low concentration of astemizole sensitizes ACC cells to doxorubicin, which is a component of the standard treatment for ACC composed of etoposide, doxorubicin, cisplatin and mitotane (EDPM). Patched uses the proton motive force to efflux drugs. This makes its function specific to cancer cells, thereby avoiding toxicity issues that are commonly observed with inhibitors of ABC multidrug transporters. Our data provide strong evidence that the use of astemizole or a derivative in combination with EDPM could be a promising therapeutic option for ACC by increasing the treatment effectiveness at lower doses of EDPM, which would reduce the severe side effects of this regimen.
Complete list of metadata

https://hal.univ-cotedazur.fr/hal-02917455
Contributor : Isabelle Mus-Veteau <>
Submitted on : Wednesday, November 18, 2020 - 9:04:50 AM
Last modification on : Thursday, December 3, 2020 - 9:40:06 AM
Long-term archiving on: : Friday, February 19, 2021 - 6:24:25 PM

File

Hasanovic et al 2020 biomedici...
Files produced by the author(s)

Identifiers

Collections

Citation

Anida Hasanovic, Méliné Simsir, Choveau Fs, Enzo Lalli, Isabelle Mus-Veteau. Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity.. Biomedicines, MDPI, 2020, 8, ⟨10.3390/biomedicines8080251⟩. ⟨hal-02917455⟩

Share

Metrics

Record views

40

Files downloads

38